Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04445220
Recruitment Status : Recruiting
First Posted : June 24, 2020
Last Update Posted : March 16, 2021
Sponsor:
Information provided by (Responsible Party):
Sentien Biotechnologies, Inc.

Brief Summary:
The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in COVID-19 subjects with Acute Kidney Injury (AKI). SBI-101 is a biologic/device combination product designed to regulate inflammation and promote repair of injured tissue using allogeneic human mesenchymal stromal cells. SBI-101 will be integrated into the renal replacement circuit and patients will be treated for up to 24 hours.

Condition or disease Intervention/treatment Phase
COVID-19 Acute Kidney Injury Biological: SBI-101 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy
Actual Study Start Date : November 19, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Low dose cohort
SBI-101 device containing 250 million MSCs
Biological: SBI-101
SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.

Experimental: High dose cohort
SBI-101 device containing 750 million MSCs
Biological: SBI-101
SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.

No Intervention: Case controls
Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants.



Primary Outcome Measures :
  1. Safety and tolerability as measured by incidence of IP-related serious adverse events [ Time Frame: Outcomes and Serious Adverse Events through Day 180 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Laboratory confirmed COVID-19 diagnosis
  • AKI as determined by the Investigator based on his/her clinical judgment
  • Receiving or planned to receive RRT in < 24 hours
  • Able to tolerate indwelling intravascular access
  • Has tolerated CRRT for at least 6 hours prior to IP treatment
  • Likely to require RRT for at least an additional 48 hours
  • Potassium level >3.6 and <5.5 mEq/L or >3.6 and < 5.5 mmol/L prior to IP treatment
  • SaO2 > 92% prior to IP initiation
  • Blood pH > 7.2 prior to IP initiation
  • Medically cleared to receive anticoagulation per institutional standard of care / PI prescribed protocol
  • Ability to give informed consent or have a legally authorized representative do so

Exclusion Criteria:

  • Female subjects who are pregnant, planning to become pregnant, or lactating
  • MAP <70 mmHg immediately prior to IP initiation
  • Systolic blood pressure < 90 mmHg immediately prior to IP initiation
  • Mechanical ventilator support requiring FiO2 > 80% prior to IP initiation
  • Receiving extracorporeal membrane oxygenation (ECMO)
  • Liver disease with Child Pugh score of > 7 prior to IP initiation
  • High sensitivity cardiac Troponin level (hs-cTn) > 100.0 ng/L prior to IP initiation
  • Hepatorenal syndrome
  • AKI due to post-renal outflow obstruction
  • Acute or chronic vasculitis of any etiology
  • Chronic systemic infection
  • Subjects with a past medical history of an inherited or acquired hypercoagulable condition independent of COVID-19
  • Patients with a past medical history of an allergic response to MSC therapy
  • Participation in another interventional trial with the exception of studies of antivirals, corticosteroids, hydroxychloroquine, azithromycin, or angiotensin converting enzyme inhibitors/angiotensin receptor blockers (or related compounds)
  • Active malignancy(-ies) and/or receiving active treatment for a malignancy(-ies), with the exception of non-melanoma skin cancer
  • Subjects, who in the opinion of the Investigator, are likely to require escalating doses of vasopressors to attain and/or maintain hemodynamic stability
  • Imminent death in <24 hours
  • Organ failure affecting more than 2 non-renal organs
  • Platelet count <50,000/μL or other serious hematological abnormalities that would place subject in imminent danger of death
  • Lactate levels >8 mmol/L suggestive of severe end-organ hypoperfusion prior to the time of IP integration
  • Any prior medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04445220


Contacts
Layout table for location contacts
Contact: Brian Miller 781-361-9031 ext 101 brian.miller@sentienbiotech.com

Locations
Layout table for location information
United States, New Mexico
University of New Mexico School of Medicine Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: J. Pedro Teixeira, MD         
Sponsors and Collaborators
Sentien Biotechnologies, Inc.
Layout table for additonal information
Responsible Party: Sentien Biotechnologies, Inc.
ClinicalTrials.gov Identifier: NCT04445220    
Other Study ID Numbers: SBI-101-02
First Posted: June 24, 2020    Key Record Dates
Last Update Posted: March 16, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sentien Biotechnologies, Inc.:
CRRT
AKI
Continuous renal replacement therapy
MSC
Mesenchymal stromal cells
Mesenchymal stem cells
Stem cells
Cell therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Wounds and Injuries
Renal Insufficiency
Kidney Diseases
Urologic Diseases